![Mathias Locher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perfil
Mathias Locher is currently the Chief Development Officer at Covagen AG.
Previously, he held the position of Vice President-PreClinical Development at Micromet AG.
From 2007 to 2011, he worked at Merck Serono SA as the Global Head-Drug Metabolism & Pharmacokinetics.
He also served as the Chief Development Officer at Heidelberg Pharma AG from 2021 to 2023.
Dr. Locher obtained a doctorate degree from Eberhard Karls Universität Tübingen.
Antiguos cargos conocidos de Mathias Locher.
| Empresas | Cargo | Fin |
|---|---|---|
| HEIDELBERG PHARMA AG | Corporate Officer/Principal | 01/04/2023 |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Corporate Officer/Principal | 04/06/2020 |
Merck Serono SA
 Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Corporate Officer/Principal | 01/01/2011 |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs | Corporate Officer/Principal | - |
Formación de Mathias Locher.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
17
Relaciones de 1er grado
5
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs | Health Technology |
Heidelberg Pharma AG
 Heidelberg Pharma AG Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
- Bolsa de valores
- Insiders
- Mathias Locher
